Ani Pharmaceutic Stock Price, News & Analysis

ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its second quarter 2025 financial results announcement for Friday, August 8, 2025, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results.

Key executives participating in the call include CEO Nikhil Lalwani, CFO Stephen P. Carey, Head of Rare Disease Chris Mutz, and Chief Medical Officer Mary Pao, M.D., Ph.D. Investors can access the call via toll-free number 800-343-4136 using conference ID 5034065. A webcast will be available on the company's website under the Investors section.

ANI Pharmaceuticals (NASDAQ:ANIP) announced results from the NEW DAY clinical trial evaluating ILUVIEN® for diabetic macular edema (DME) treatment. The study compared ILUVIEN to aflibercept in treatment-naïve patients.

The trial's primary endpoint of reducing supplemental aflibercept injections was not met in the intent-to-treat population (2.4 vs 2.5 injections, p=0.756). However, a secondary endpoint showed significantly longer time between treatments with ILUVIEN (185.4 vs 132.8 days, p<0.001). A post-hoc analysis of patients without protocol deviations showed significant reduction in supplemental injections for the ILUVIEN group (1.8 vs 2.5, p=0.029).

Safety data showed ILUVIEN was well-tolerated but had higher treatment-related adverse events (41%) compared to aflibercept (3%), mainly related to cataracts and increased intraocular pressure.

ANI Pharmaceuticals (NASDAQ:ANIP) announced its participation in the upcoming Leerink Partners Therapeutics Forum, focusing on I&I and Metabolism. The company's President and CEO, Nikhil Lalwani, will be conducting one-on-one meetings with investors during the event, which takes place on July 8, 2025, in Boston, MA.

ANI Pharmaceuticals presented new preclinical data for Purified Cortrophin Gel at EULAR 2025 Congress, demonstrating promising results in treating murine collagen-induced arthritis. The study showed that repository corticotropin injection (RCI) significantly reduced joint swelling and inflammatory cytokine response in mice, particularly at the 400 U/kg dose, without causing additional bone loss. The research, led by experts from UC San Diego and UC Davis, supports ANI's commitment to understanding their product's mechanism of action. Cortrophin Gel is currently indicated for short-term administration as adjunctive therapy in rheumatoid arthritis, including juvenile rheumatoid arthritis.

ANI Pharmaceuticals (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani will present at the upcoming 2025 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, June 4, 2025, at 2:35 PM ET.

Investors can access the live and archived webcast through ANI Pharmaceuticals' website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replay will be available for 60 days after the event. Interested parties can schedule one-on-one meetings with the company by contacting their Jefferies representative.

ANI Pharmaceuticals (NASDAQ: ANIP) has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's presentation is scheduled for Tuesday, May 20, 2025, at 1:30pm ET. CEO Nikhil Lalwani and CFO Stephen Carey will represent the company at the conference.

Investors can access the presentation through a live webcast on ANI's website under the Investors section. The webcast recording will remain available for 90 days after the event. One-on-one meetings with management can be arranged through meetings@hcwco.com.

ANI Pharmaceuticals (ANIP) reported exceptional Q1 2025 financial results and raised its full-year guidance. The company achieved record quarterly revenues of $197.1 million, up 43.4% year-over-year. Key highlights include Rare Disease revenues of $69.0 million, with Cortrophin Gel generating $52.9 million (+43.1% YoY) and ILUVIEN/YUTIQ contributing $16.1 million. Generics revenue grew 40.5% to $98.7 million. The company delivered record adjusted EBITDA of $50.7 million (+34.9% YoY) and adjusted EPS of $1.70. Based on strong performance, ANI raised its 2025 guidance, now expecting revenues of $768-793 million and adjusted EPS of $6.27-6.62. The company maintains a strong U.S. footprint with over 90% of revenues from U.S.-manufactured goods.

ANI Pharmaceuticals (NASDAQ: ANIP) presented preclinical data on Purified Cortrophin® Gel in an experimental autoimmune uveitis (EAU) mouse model at the ARVO 2025 annual meeting. The study demonstrated that Cortrophin Gel showed a significant dose-dependent effect in suppressing EAU across all tested doses (4, 40, 160, and 400 U/kg), with the strongest suppression at 400 U/kg.

Key findings revealed that the treatment suppressed inflammatory cytokine production and reduced retinal damage caused by EAU, comparable to α-MSH treatment versus placebo. The research supports the company's understanding of Cortrophin Gel's mechanism of action and demonstrates ANI's commitment to expanding clinical research for their products.

ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its first quarter 2025 financial results announcement for Friday, May 9, 2025, before market opening. The company will host a conference call at 8:00 a.m. ET to discuss the results.

Key executives participating in the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call via toll-free number 800-225-9448 using Conference ID 4921902.

The webcast will be available live and for replay on the company's website under the Investors section. A replay option will be accessible for two weeks by calling 800-753-8591 with access code 4921902.